Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA advisory committee votes in favor of COVID-19 pill molnupiravir

By Brian Buntz | November 30, 2021

Merck/RidgebackBioFDA’s Antimicrobial Drugs Advisory Committee narrowly concluded that the benefits of Merck’s (NYSE:MRK) COVID-19 pill molnupiravir outweigh the risks.

A total of 13 members of the panel voted in favor of the drug candidate, while 10 voted against it. There were no abstentions.

FDA generally follows the advice of its advisory committees.

“This was clearly a very difficult decision,” said Dr. Michael D. Green, a member of the advisory committee and professor at the University of Pittsburgh School of Medicine. “I would use it in high-risk non-vaccinated individuals,” Green said, adding he would consider the drug for people with obesity and multiple other risk factors. “For pregnancy, I would only use it if there’s no alternative therapy available, and I don’t think I would use it in the first trimester.”

Committee members who voted ‘no’ voiced several concerns.

Dr. Timothy Burgess of the Uniformed Services University cited the unconvincing clinical data for his ‘no’ vote. “And I think there are concerns with respect to the uncertainty about the risk for genotoxicity,” he added. “I certainly recognize the need for additional therapeutic agents to be available, particularly with the emergence of developing clades and strains,” Burgess said. “But on the as the question is articulated on the basis of the available data, I voted ‘no.’”

Committee member Dr. Jennifer Le said she appreciated the pharmacologic safety data Merck provided, “yet the pre-marketing studies that we’ve seen here demonstrate highly relevant signals for safety concerns,” said Le, who is a professor of clinical pharmacy at UC San Diego.

Merck’s stock jumped $1.95% to $76.37 in after-hours trading.

Merck developed the drug in collaboration with Ridgeback Biotherapeutics.

If FDA decides to grant emergency use authorization to the drug, it would be the first oral COVID-19 antiviral available in the U.S.

The UK granted conditional approval to the drug in early November.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: Antimicrobial Drugs Advisory Committee, FDA, Merck, Molnupiravir, Ridgeback Biotherapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50